Survival and Neurodevelopmental Outcome of Young Children With Medulloblastoma at St Jude Children's Research Hospital

Walter, Andrew W.; Mulhern, Raymond K.; Gajjar, Amar; Heideman, Richard L.; Reardon, David A.; Sanford, Robert A.; Xu, Xiaoping; Kun, Larry E.

doi:10.1200/jco.1999.17.12.3720

Cited by 210 publications

(151 citation statements)

References 37 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…Confirming previous findings, 8,10,33,36,55,56 survivors who were treated with CRT alone or, to a much lesser extent, in combination with IT MTX reportedly had the poorest educational outcomes. Difficulties in Mathematics have been reported previously among survivors of acute lymphocytic leukemia who were treated with prophylactic CRT and IT MTX.…”

Section: Discussionsupporting

confidence: 74%

Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics

Barrera

Shaw

Speechley

et al. 2005

Cancer

285

265

View full text Add to dashboard Cite

The protein human CC chemokine ligand 2 (CCL2, also known as monocyte chemoattractant protein 1 or MCP‐1) has been synthesized using a combination of solid phase peptide synthesis (SPPS) and native chemical ligation (NCL). The thioester‐peptide segment was synthesized using the sulfonamide safety‐catch linker and 9‐fluorenylmethoxycarbonyl (Fmoc) SPPS, and pseudoproline dipeptides were used to facilitate the synthesis of both CCL2 fragments. After assembly of the full‐length peptide chain by NCL, a glutathione redox buffer was used to fold and oxidize the CCL2 protein. Synthetic human CCL2 binds to and activates the CCR2 receptor on THP‐1 cells, as expected. CCL2 was crystallized and the structure was determined by X‐ray diffraction at 1.9‐Å resolution. The structure of the synthetic protein is very similar to that of a previously reported structure of recombinant human CCL2, although the crystal form is different. The functional CCL2 dimer for the crystal structure reported here is formed around a crystallographic twofold axis. The dimer interface involves residues Val9‐Thr10‐Cys11, which form an intersubunit antiparallel β‐sheet. Comparison of the CCL2 dimers in different crystal forms indicates a significant flexibility of the quaternary structure. To our knowledge, this is one of the first crystal structures of a protein prepared using the sulfonamide safety‐catch linker and NCL. © 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 94: 350–359, 2010. This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at biopolymers@wiley.com

show abstract

Section: Discussionsupporting

confidence: 74%

Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics

Barrera

Shaw

Speechley

et al. 2005

Cancer

285

265

View full text Add to dashboard Cite

show abstract

“…As a consequence of current treatment strategies, however, patients often suffer from life-long disabilities and cognitive dysfunction. It is estimated that 90% of medulloblastoma survivors have impaired intelligence, and 40 -100% of long-term survivors have some degree of cognitive dysfunction (Walter et al, 1999;Palmer et al, 2001;Packer et al, 2003b). Radiation and chemotherapy also often lead to significant endocrine abnormalities, including thyroid, growth, and gonadal dysfunction (Xu et al, 2004).…”

mentioning

confidence: 99%

Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome

et al. 2005

View full text Add to dashboard Cite

Survivin is an apoptotic inhibitor that is expressed at high levels in a variety of malignancies. Survivin has four known alternative splice forms (Survivin, Survivin-2B, Survivin-deltaEx3, and Survivin-3B), and the recent literature suggests that these splice variants have unique functions and subcellular localisation patterns. We evaluated 19 fresh-frozen paediatric medulloblastomas for the expression of three Survivin isoforms by quantitative PCR. Survivin was most highly expressed when compared with normal cerebellar tissue. We also investigated Survivin protein expression in 40 paraffin-embedded paediatric medulloblastoma tumours by immunohistochemistry. We found a statistically significant association between the percentage of Survivin-positive cells and histologic subtype, with the large-cell-anaplastic variant expressing Survivin at higher levels than the classic subtype. We also found a statistically significant relationship between the percent of Survivin-positive cells in the tumours and clinical outcome, with higher levels of Survivin correlating with a worse prognosis. In summary, our study demonstrates a role for Survivin as a marker of tumour morphology and clinical outcome in medulloblastoma. Survivin may be a promising future prognostic tool and potential biologic target in this malignancy.

show abstract

“…4,5 However, many patients suffer neuropsychological sequelae and neurocognitive decline. 6,7 Furthermore, chemotherapy regimens are usually platinum-based, and platinum agents are associated with significant ototoxicity. This may contribute to developmental delay as well.…”

mentioning

confidence: 99%

Intraarterial chemotherapy and osmotic blood‐brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system

Jahnke

Kraemer

Knight

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. The rate of durable responses in embryonal and certain germ cell tumors of the central nervous system (CNS) is unsatisfactory. Intraarterial chemotherapy and osmotic blood‐brain barrier disruption (IA/BBBD) increases drug delivery to the CNS. METHODS. Data of patients treated with carboplatin or methotrexate‐based IA/BBBD on prospective phase 2 trials conducted at 3 centers were collected. Study outcomes included overall survival (OS), time to progression (TTP), and toxicity. RESULTS. Fifty‐four patients were treated. Twenty‐seven patients received IA/BBBD as salvage treatment. The median OS was 2.8 years for all patients, 2.5 years for supratentorial and disseminated primitive neuroectodermal tumors (PNETs, n = 29), 1.7 years for medulloblastomas (n = 12), and 5.4 years for germ cell tumors (n = 13). OS and TTP for all patients were better with a Karnofsky Performance Status ≥70% (P = .0013 and .0070) and IA/BBBD as first‐line treatment (P = .0059 and .029). In PNETs, OS was higher with pineal location (P = .045) and IA/BBBD as first‐line treatment (P = .0036), and TTP was improved with radiotherapy before IA/BBBD (P = .036) and IA/BBBD as first‐line treatment (P = .0079). Seventeen of 54 patients (31%) are alive, and 16 are alive at 4+ to 18+ years. Three survivors were not treated with radiotherapy and 4 were treated with focal radiotherapy only. The patients who were not irradiated did not develop dementia. CONCLUSIONS. Survival and toxicity data appear promising, considering the cohort's adverse prognostic profile. A plateau in survival curves suggests a cure for some patients. Long‐term survival may be achieved with focal or reduced‐dose radiotherapy in some IA/BBBD patients. Cancer 2008. © 2007 American Cancer Society.

show abstract

Survival and Neurodevelopmental Outcome of Young Children With Medulloblastoma at St Jude Children's Research Hospital

Cited by 210 publications

References 37 publications

Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics

Educational and social late effects of childhood cancer and related clinical, personal, and familial characteristics

Survivin, Survivin-2B, and Survivin-deItaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome

Intraarterial chemotherapy and osmotic blood‐brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system

Contact Info

Product

Resources

About